C.Q. Pharmaceutical Holding Co., Ltd. Class A

As of March 31, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A carries a market capitalization of 9.85B, placing it among publicly traded companies globally. Its enterprise value stands at 35.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

C.Q. Pharmaceutical Holding Co., Ltd. Class A's next confirmed earnings release is scheduled for October 24, 2026.

As of March 31, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A has 1.73B shares outstanding.

As of March 31, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 21.69. The price-to-sales ratio is 0.12, and the price-to-book ratio stands at 0.84.

As of March 31, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A trades at an EV/EBITDA multiple of 47.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 47.91 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 35.15B versus a market cap of 9.85B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A maintains a current ratio of 1.20, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 150.17, indicating elevated leverage, while an interest coverage ratio of 1.00 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A posted a return on equity (ROE) of 3.96, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.44 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.67, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.24, useful for judging operating efficiency across full business cycles. The company generates approximately 6.28M in revenue per employee across its workforce of 13,028.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.64 indicates how many times C.Q. Pharmaceutical Holding Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A recorded 150.64M in income tax expense. That works out to an effective tax rate of 20.72, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 726.95M, leaving 455.70M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A's stock has declined approximately 6.31% over the past 52 weeks. The 50-day moving average sits at 5.39, while the 200-day moving average is 5.71.

Over the twelve months ended March 31, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A generated 81.86B in revenue and converted that into 455.70M in net income, yielding earnings per share of 0.33. EBITDA reached 733.65M, while operating income came in at 1.96B.

As of March 31, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A holds 4.89B in cash and equivalents against 25.15B in total debt, resulting in a net debt position of 18.07B. Total book value stands at 11.71B, with working capital of 9.72B providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A posted a gross margin of 7.16, reflecting its pricing power and cost economics. The operating margin of 2.39 and net profit margin of 0.56 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A paid dividends of 0.50 per share. The dividend payout ratio of 124.44 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -15.87, meaning C.Q. Pharmaceutical Holding Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

C.Q. Pharmaceutical Holding Co., Ltd. Class A's most recent stock split took place on April 16, 2010 with a 2:3 split ratio.

As of March 31, 2026, C.Q. Pharmaceutical Holding Co., Ltd. Class A has an Altman Z-Score of 1.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.